Search





Search





Markets
/
Stocks
/
nasdaq-uncy
/

Unicycive Therapeutics Inc

UNCY

Add to Watchlist

8.260USD

-0.300-3.50%

Close 05/15, 16:00（ET）Quotes delayed by 15 min

220.54MMarket Cap

LossP/E TTM



Unicycive Therapeutics Inc

8.260

-0.300-3.50%

Overview Financials Discussions Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Discussions

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Unicycive Therapeutics Inc

Currency: USD Updated: 2026-05-15

Key Insights

Unicycive Therapeutics Inc's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is significant.Its valuation is considered fairly valued, ranking 115 out of 382 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 38.50.In the medium term, the stock price is expected to trend up.Despite a good stock market performance and strong technicals over the past month, the fundamentals don't support the current trend.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Unicycive Therapeutics Inc's Score

Industry at a Glance

Industry Ranking

115 / 382

Overall Ranking

241 / 4482

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Negative

Unicycive Therapeutics Inc Highlights

StrengthsRisks

Unicycive Therapeutics, Inc. is a biotechnology company developing treatments for kidney diseases. The Company's lead drug candidate, oxylanthanum carbonate (OLC), is an investigational phosphate binding agent being developed for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis. Its second asset, UNI-494, is a patent-protected new chemical entity in clinical development for the treatment of conditions related to acute kidney injury.

Undervalued

The company’s latest PE is -3.67, at a low 3-year percentile range.

Institutional Buying

The latest institutional holdings are 9.56M shares, increasing 4.50% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 0.00 shares of this stock.

Analyst Rating

Based on 9 analysts

Buy

Current Rating

38.500

Target Price

+349.77%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-05-15

The current financial score of Unicycive Therapeutics Inc is 3.94, ranking 381 out of 382 in the Biotechnology & Medical Research industry. Its financial status is robust, and its operating efficiency is low.

Score

Industry at a Glance

Previous score

3.94

Change



Financials

10.00

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

0.00

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

0.00

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

4.70

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

5.00

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Unicycive Therapeutics Inc's Company Valuation

Currency: USD Updated: 2026-05-15

The current valuation score of Unicycive Therapeutics Inc is 7.33, ranking 128 out of 382 in the Biotechnology & Medical Research industry. Its current P/E ratio is -3.67, which is -520.31% below the recent high of 15.42 and -32.58% above the recent low of -4.86.

Score

Industry at a Glance

Previous score

7.33

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 115/382

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-05-15

The current earnings forecast score of Unicycive Therapeutics Inc is 8.25, ranking 143 out of 382 in the Biotechnology & Medical Research industry. The average price target is 43.00, with a high of 90.00 and a low of 21.00.

Score

Industry at a Glance

Previous score

8.22

Change

0.03

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 9 analysts

Buy

Current Rating

38.500

Target Price

+349.77%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

554

Total

Median

Average

Company name

Ratings

Analysts

Unicycive Therapeutics Inc

UNCY

CRISPR Therapeutics AG

CRSP

argenx SE

ARGX

IQVIA Holdings Inc

IQV

Beigene Ltd

ONC

Ionis Pharmaceuticals Inc

IONS

...

111

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-05-15

The current price momentum score of Unicycive Therapeutics Inc is 9.41, ranking 12 out of 382 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 9.02 and the support level at 7.22, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

9.70

Change

-0.29

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(3)

Neutral(2)

Buy(2)

Indicators

Value

Direction

MACD(12,26,9)

0.102

Buy

RSI(14)

62.699

Neutral

STOCH(KDJ)(9,3,3)

68.131

Sell

ATR(14)

0.398

High Vlolatility

CCI(14)

90.815

Neutral

Williams %R

28.402

Buy

TRIX(12,20)

0.769

Sell

StochRSI(14)

2.861

Sell

Moving Average

Sell(1)

Neutral(0)

Buy(5)

Indicators

Value

Direction

MA5

8.290

Sell

MA10

8.144

Buy

MA20

7.766

Buy

MA50

7.163

Buy

MA100

6.774

Buy

MA200

5.789

Buy

Institutional Confidence

Currency: USD Updated: 2026-05-15

The current institutional shareholding score of Unicycive Therapeutics Inc is 3.00, ranking 193 out of 382 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 35.81%, representing a quarter-over-quarter increase of 15.41%. The largest institutional shareholder is James Simons, holding a total of 24.40K shares, representing 0.09% of shares outstanding, with 1.00% increase in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Vivo Capital, LLC

1.79M

Millennium Management LLC

1.17M

+15.55%

Octagon Capital Advisors LP

1.00M

Nantahala Capital Management, LLC

939.20K

Great Point Partners, LLC

796.56K

Gupta (Shalabh K)

597.25K

-0.02%

Logos Global Management LP

473.56K

Citadel Advisors LLC

258.30K

+519.81%

Rosalind Advisors, Inc.

242.49K

Risk Assessment

Currency: USD Updated: 2026-05-15

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Unicycive Therapeutics Inc is 3.80, ranking 114 out of 382 in the Biotechnology & Medical Research industry. The company's beta value is 1.78. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. with an industry-leading ESG disclosure.